Studer, A. GarciaRojas-Gimenez, M.Feijoo, M. VellosoRomero-Barco, C. M.Godoy-Navarrete, F.Mena-Vazquez, N.2023-05-032023-05-032022-06-01Studer AG, Rojas-Giménez M, Feijoo MV, Romero-Barco CM, Godoy-Navarrete F, Mena-Vázquez N. AB1112 SARS-COV-2 INFECTION AND IT VACCINATION IN AUTOINMUNE DISEASE-ASSOCIATED INTERSTICIAL LUNG DISEASE. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):1673.2-1673.0003-4967http://hdl.handle.net/10668/20074Background: Intersticial lung disease (ILD) is a common condition in patients with systemic autoinmune diseases (SAI) that is characterized by increased morbility and mortality. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has posed huge challenges worldwide and previous studies suggest that ILD patients experience a more severe clinical course. Objectives: To analyze COVID-19 infection effects in patients with ILD associated systemic autoinmune disease (ILD-SAI) and to describe their vaccination status. Methods: Design We performed a multicenter, retrospective, observational study from 6 teaching hospitals in Andalusia, Spain. Study protocol We included ILD-SAI patients: rheumatoid arthritis (RA), systemic sclerosis (SS) and inflammatory myopathies (IM), assisted in reumatology consultations in 2021. Variables COVID-19 infection was the main variable that we collected and it was confirmed by a positive result on a PCR test.enÁrea de Gestión Sanitaria Sur de Sevillaconference outputopen access10.1136/annrheumdis-2022-eular.18251468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/1673.2.full.pdf850279007051